Get the Daily Brief

All action, no filler. BioBriefs delivers the industry’s 10 must-know updates, every morning.

Latest Biotech News

Ebola—CEPI-backed mRNA push for Bundibugyo outbreak

June 15, 2026

Moderna and CEPI moved to accelerate development of an mRNA vaccine targeting the Bundibugyo virus species driving the current Ebola outbreak in the Democratic Republic of the Congo and Uganda....

Cell therapy—outpatient CAR T concept data at EHA

June 15, 2026

Legend Biotech’s CD19/CD20 dual-target CAR T LB-2501 posted first-in-human updates at EHA2026 that aim to support development as an off-the-shelf, single-infusion, outpatient CAR T approach....

Biotech capital markets—record IPO prices and raises

June 15, 2026

Parabilis Medicines set a new U.S. biotech IPO record by pricing its offering and raising gross proceeds of $770.5 million after an upsized launch. The company entered Nasdaq trading at the high...

Biotech policy and security oversight—US-funded global biolabs evidence

June 15, 2026

ODNI Director Tulsi Gabbard released declassified information asserting evidence of U.S. taxpayer funding for more than 120 biolabs across over 30 countries. The ODNI release claims the...

Rare disease gene therapy finance—priority review voucher monetization

June 15, 2026

Rocket Pharmaceuticals sold an FDA drug review fast pass tied to the accelerated approval of Kresladi for a rare pediatric indication, securing $180 million in non-dilutive capital. Rocket said...

Aging and safety signals—GLP-1 associated hypotensive events

June 15, 2026

Northwestern Medicine researchers reported a safety concern tied to glucagon-like peptide-1 receptor agonists, linking GLP-1 use to higher rates of fainting and dizziness. The analysis focused on...

Metabolic drug outcomes—semaglutide and fracture risk

June 15, 2026

Stanford University researchers reported retrospective cohort findings suggesting semaglutide is associated with a reduced risk of bone fractures. The analysis used electronic health record data...

Genomics diagnostics—first-tier long-read sequencing rollout

June 15, 2026

Implementation data from the Netherlands suggest long-read genome sequencing can streamline rare-disease diagnostics when used as a first-tier test. Presenters at the European Society of Human...

Renal transplant pharmacogenomics—genetics-guided tacrolimus dosing

June 15, 2026

A 2026 study in BMC Pharmacology and Toxicology reported that CYP3A5 genetic variability can be used to tailor tacrolimus dosing in pediatric renal transplant patients. The work focused on...

Semaglutide safety signals tied to bone outcomes

June 14, 2026

Semaglutide use was associated with a reduced risk of bone fractures in a large retrospective cohort study using data from more than 161 million patients across U.S. hospitals and academic...

Record biotech IPO capital formation

June 14, 2026

Parabilis Medicines priced what it is described as the largest-ever U.S. IPO by a drug developer, raising $770.5 million in gross proceeds after an upsized offering that began with 33.5 million...

FDA rare-disease pathway financing via priority review voucher

June 14, 2026

Rocket Pharmaceuticals said it received $180 million by selling an FDA drug review priority review voucher tied to the accelerated approval of Kresladi in March for a pediatric rare disease. The...

Cell therapy expansion at EHA: off-the-shelf CAR T with no lymphodepletion

June 14, 2026

Legend/Legend Biotech presented first-in-human data for LB-2501, a CD19/CD20 dual-targeting CAR T designed for an off-the-shelf approach with no lymphodepletion, at EHA2026. Investigators reported...

Checkpoint combination approval for high-risk clear cell RCC

June 14, 2026

The FDA approved an adjuvant regimen combining pembrolizumab with belzutifan for adults with high-risk clear cell kidney cancer following surgery. The approval is supported by a Dana-Farber study...

Biotech IP and manufacturing risks tied to US government action

June 14, 2026

WuXi AppTec filed a lawsuit in U.S. District Court for the District of Columbia contesting its designation as a Chinese military company. The company argues the 1260H listing has already caused...

Rare disease genetics: long-read sequencing implementation in the Netherlands

June 14, 2026

Researchers in the Netherlands reported early implementation results suggesting that long-read genome sequencing as a first-tier test can reduce time to diagnosis and follow-up testing, even if...

Long-read rare disease testing: new comprehensive test and published evidence

June 14, 2026

Radboud University Medical Center and Maastricht UMC+ published results describing clinical long-read genome sequencing as a route to more accurate and efficient diagnosis of rare genetic...

Ebola vaccine R&D: Moderna mRNA candidate accelerated with CEPI funding

June 14, 2026

Moderna and CEPI said they are advancing an investigational mRNA vaccine targeting Bundibugyo virus—the species driving an ongoing Ebola outbreak in the Democratic Republic of the Congo and...

AI in endocrine care: screening for underdiagnosed primary aldosteronism

June 14, 2026

Mayo Clinic researchers reported an AI-driven screening model designed to detect primary aldosteronism (PA), a frequently underdiagnosed cause of hypertension that can drive cardiovascular...

Hematology - off-the-shelf CAR T with outpatient intent

June 14, 2026

Legend Biotech’s LB-2501 is showing early efficacy with a safety profile that is enabling investigators to frame a future outpatient CAR T approach. At EHA2026, Lei Fan of First Affiliated...